Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.

Hope, William W; Warn, Peter A; Sharp, Andrew; Howard, Susan; Kasai, Miki; Louie, Arnold; Walsh, Thomas J; Drusano, George L; Denning, David W

Hope, William W; Warn, Peter A; Sharp, Andrew; Howard, Susan; Kasai, Miki; Louie, Arnold; Walsh, Thomas J; Drusano, George L; Denning, David W.

Affiliation

Hope WW; Pediatric Oncology Branch, NCI/NIH, CRC Rm. 1-5750, 10 Center Dr., MSC 1100, Bethesda MD 20892-1100, USA. hopew@mail.nih.gov

Antimicrob Agents Chemother ; 50(11): 3680-8, 2006 Nov.

Article in En | MEDLINE | ID: mdl-16954320

Subject(s)

Antifungal Agents/pharmacology; Candida albicans/drug effects; Candida albicans/genetics; Flucytosine/pharmacology; Bayes Theorem; Candida albicans/growth & development; Candidiasis/microbiology; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Genotype; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Survival; Time Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Candida albicans / Flucytosine / Antifungal Agents Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2006 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google